Bearing in mind the importance of upper-body obesity for the insulin resistance (or metabolic) syndrome and the abnormalities in free fatty acid metabolism associated with this disorder, the regulation of lipolysis in isolated subcutaneous adipocytes was investigated in 13 72-yr-old upper-body obese men with insulin resistance and glucose intolerance and in 10 healthy 72-yr-old men.
Introduction
Upper-body obesity is an important risk factor for the development of hypertension, dyslipidemia, and non-insulin-dependent diabetes mellitus (NIDDM)' (1, 2, 3) . Several of these conditions occur simultaneously and have been recognized as the insulin resistance or "metabolic" syndrome as discussed (4, 5, 6) .
Pathophysiological research on the metabolic syndrome has mainly focused on the interactions of insulin with various aspects of metabolism. A recent finding, for example, is that of a defect in glycogen-synthase function in NIDDM patients (7) which may be genetic (8) . However, other mechanisms, not directly related to insulin action, may also be of importance. For example, changes in the action of catecholamines, the major insulin-counteracting hormones, can be involved as well. Increased sympathetic nervous system activity is associated with insulin resistance (9) and altered sympathetic activity may be present in the metabolic syndrome (4, 10) .
The development and maintenance of obesity plays a central role in the metabolic syndrome. Central obesity may be a predominant factor for the insulin resistance in the metabolic syndrome ( 1 1-16) . Adaptation to the life style ofthe industrialized world is associated with an increased incidence of obesity and the metabolic syndrome in Pima indians and Australian aborigines as discussed ( 17) .
The mechanism behind the development of upper-body obesity is unknown but it may be the result of defects in the breakdown of triglycerides in adipocytes during lipolysis, considering that these lipids constitute > 95% of the total adipocyte weight. In humans, catecholamines are the most important lipolytic hormones, as previously reviewed ( 18) . Lipolysis in subcutaneous fat cells is stimulated via (Il and ,B2 adrenoceptors, initiating a chain of events finally activating hormone sensitive lipase (HSL). A counterregulatory system causing inhibition of lipolysis is mediated via a-2 adrenoceptors.
In the present study, lipolysis regulation in abdominal fat cells was studied in elderly male subjects with several manifestations ofthe metabolic syndrome (abdominal obesity, insulin resistance, glucose intolerance, and in some cases hypertension) and in healthy non-obese controls. Catecholamine induced lipolysis was investigated in vitro and the results were related to glucose tolerance and insulin sensitivity.
Methods
Subjects. The subjects were recruited among 72-yr-old men, all living in the same town for at least 20 years, identified during an ongoing health screening program ( 13) . 13 subjects with the metabolic syndrome were selected for the study. The following inclusion criteria were used: body mass index (BMI) > 26 kg/m2, waist-hip ratio > 0.93, insulin resistance as determined with an euglycemic hyperinsulinemic clamp, with an M/I value (insulin sensitivity index) of < 4.2 (mg/kg/ min/mU/l) indicating a high level of insulin resistance to glucose uptake and either impaired oral glucose tolerance (n = 8), or mild NIDDM (i.e., symptom-free fasting hyperglycemia, but no glucosuria) (n = 5). None had received any form ofantidiabetic therapy before the study. Three ofthe subjects were treated for essential hypertension with calcium antagonists, and one subject was on pharmacological treatment of hyperlipidemia with a fibrate, otherwise the subjects were drug free. Ten non-obese healthy and drug free subjects with normal insulin sensitivity and normal tolerance to an oral glucose load comprised a control group. The M/I value in this group was > 5.5 and the BMI < 24 kg/M2.
The clinical characteristics of the two groups are shown in Table I . All subjects had given their informed consent before entering the study. The study was approved by the ethic's committee of the Karolinska Institute and Uppsala University.
The subjects were examined in the fasting state at 8:00 a.m. on three different occasions. Insulin sensitivity was determined on the first occasion, glucose tolerance on the second. On the third occasion, the subjects first rested in the supine position for 10 min. Blood pressure was then measured with a mercury sphygmomanometer on the right arm. The systolic and diastolic pressure was determined by phases I and V of the Korotkov sounds, the values are means of three consecutive measurements. After that venous blood samples for analysis of hormones and metabolites were drawn. A subcutaneous fat specimen of -2-4 g was then surgically removed in the paraumbilical region as described (19) . The tissue was transported to the laboratory in saline at 370C.
Insulin clamp and glucose tolerance test. To determine the degree of insulin sensitivity an euglycemic hyperinsulinemic clamp was performed (13) . A priming infusion ofinsulin was given during the first 10 min, followed a continuous infusion at the rate of 56 mU/mi2 was given during 110 min, resulting in a plasma insulin concentration ofbetween 60 and 132 mU/l. The target plasma glucose concentration during the clamp was 5.3 mmol/l. This was reached within 60 min from the start ofthe insulin infusion in each subject and was maintained by a continuous infusion of glucose. An insulin sensitivity index (M/I) was obtained by dividing the M-value, i.e., the rate ofglucose infusion during the second hour of the clamp (mg glucose/kg body weight/min), by the steady state insulin concentration (mU/l) during the second hour of the clamp.
Glucose tolerance was measured with an oral glucose tolerance test (OGTT) on a second occasion. First, blood was drawn from an indwelling catheter for analysis of fasting plasma glucose and insulin levels. The subjects were then given 75 g ofglucose dissolved in water to drink. New samples for plasma glucose determination were taken 120 min after the oral glucose load. Isolation offat cells and determination offat cell size and number.
The adipose tissue was cut into small fragments ( 10-20 mg) and isolated fat cells were prepared from the fat specimens by collagenase treatment as described by Rodbell (20) . The cells were kept in an albumin buffer solution as described below and the cell density of the adipocyte suspension was kept constant through slow stirring with the aid ofa magnet. Direct microscopic determination ofthe fat cell diameter was performed according to the method of di Girolamo et al. (21 ) . An aliquot ofthe fat cell suspension was placed on a glass slide and the diameter of 100 cells was determined by examination with a Zeiss microscope equipped with a caliper scale. Lipolysis experiments. This assay has previously been described in detail (24) . A diluted suspension of isolated fat cells (5,000-10,000 cells/ml) was incubated in duplicate in 0.2 ml with or without increasing concentrations of either the natural catecholamine noradrenaline, the nonselective fl-adrenergic agonist isoprenaline, the f2-selective agonist terbutaline, the flI-selective agonist dobutamine, the a2-selective agonist clonidine, forskolin (which stimulates the adenylyl cyclase), or dibutyryl cyclic AMP (dcAMP) (which is a phosphodiesterase resistant cAMP analogue). All incubations were performed in duplicate at 37°C in Krebs Ringer phosphate buffer, pH 7.4, supplemented with bovine serum albumin (20 g/l), glucose (1 g/l), and ascorbic acid (0.1 g/l). In the clonidine experiments adenosine deaminase (1 mU/1) was added to the incubation medium to remove traces of adenosine which might interfere with the antilipolytic effect of clonidine. This addition was not necessary in the experiments with the lipolytic agents as previously discussed (25) . After 2 h, an aliquot was removed for determination of glycerol, which was used as lipolysis index, with an ultrasensitive automated bioluminescence assay (26) .
All agonists caused a dose-dependent stimulation or inhibition of glycerol release reaching a plateau at the highest agonist concentrations. We have previously shown that terbutaline and dobutamine are selective and full 3-adrenergic agonists in subcutaneous human fat cells (27) . The sensitivity to agonist action was defined as the pD2 value, i.e., the negative logarithm ofthe ED50 value, defined as the concentration of each drug giving half maximum effect. The ED50 value was determined using linear regression analysis of log-logit transformation ofthe individual dose-response curves. Lipolysis rates in the absence of or in the presence of maximum effective agonist concentrations were related to fat cell number, or lipid weight ofthe incubated fat cells. The maximum lipolytic effects are indicative of agonist responsiveness.
Radioligand binding assay. The receptor binding studies were also performed on isolated fat cells as has been described in detail (28) . The nonselective fl-adrenergic antagonist '25I-cyanopindolol was used in saturation and displacement experiments. Fat cells were incubated for 60 min, in a concentration of about 20,000 cells/ml, at 37°C in 0.5 ml of KRP buffer, pH 7.4, with bovine serum albumin (5 g/l), glucose ( 1 g/l) and ascorbic acid.
In the saturation experiments the fat cells were incubated with 10, 50, 100, 250, 500, and 750 pmol/l of '251I-cyanopindolol. The incubations were performed in duplicate. In a third set of tubes nonspecific binding was determined by addition ofpropranolol (0.1 mol/l). This was 30% at low and 45% at high radioligand concentrations, respec-tively. The total amount of radioactivity was determined in a fourth row ofcell-free tubes. At the end ofthe incubation, cell bound radioactivity was measured after addition of ice-cold saline and filtering through a Whatman GF/C filter (Whatman Inc., Clifton, NJ).
In the displacement experiments 1251I-cyanopindolol binding (100 pmol/l) was displaced by the highly selective #2-adrenoceptor antagonist ICI 118,551 in 12 increasing concentrations (0, I0-l-I04 mol/ 1). Nonspecific binding, defined as the binding in the presence of 10-' mol/l of ICI 1 8,551, was -30%.
The saturation experiments were evaluated by linear regression analysis of Scatchard plots (29) giving an estimate ofthe total number ofbinding sites. The Scatchard plots were always linear, indicating that the radioligand binds to the receptor subtypes with identical affinity. Since the displacing ligand ICI 1 8,551 binds to iB2 receptors with high affinity and to al -receptors with low affinity, the displacement experiments gave shallow biphasic curves. A nonlinear least squares regression analysis ofthe displacement curves provides a statistical comparison between a one-and a two-site model (30) . From the best fitted two site curve it is possible to determine the proportion ofbinding sites with high-(,32-receptors) and low-affinity (I1-receptors) for the displacing ligand, respectively.
Assuming that the concentrations of '251I-cyanopindolol used here are not sufficiently high to identify pl3-receptor binding sites, for which the radioligand has low affinity (31, 32 ) the results of the saturation and displacement experiments can be taken together to provide an estimate of the total number of both #Il-and 32-receptor binding sites for each subject. The binding assays required large amounts of fat. They could therefore only be performed in 10 obese and eight nonobese subjects, respectively. mRNA assay. For this assay, which has been described in detail (33) , -150 ,l ofisolated fat cells were homogenized and digested with protein kinase, total nucleic acids (TNA) were extracted with phenolchloroform. The amount of DNA and TNA in the extract were determined fluorometrically (34) .
Complementary oligonucleotide probes corresponding to nucleotide 739-789 for the fBI-receptor and to nucleotide 772-822 for the 32-receptor were synthesized and cloned into pGEM-3. This plasmid was then used for in vitro synthesis of cRNA which was radiolabeled with [35SJUTP. The amounts of #I-and p2-receptor mRNA in the extract were then determined in duplicate by solution hybridization (35) . The assay has previously been described in detail (33) . Briefly, [35S]UTP cRNA was hybridized at 70'C to the TNA samples. Nonhybridized material was digested with RNase. RNase resistant material was precipitated and collected on a glass filter. The results ofthe sample hybridization were compared with hybridization to a known amount of in vitro synthesized j1-and #2-receptor mRNA complementary to the radioactive probe. The results were related to the amount of TNA or DNA as described before (36) . Previous methodological experiments have shown that the fl-adrenoceptor probes are specific for the investigated species (33) and that the amount of #1-and fB2-receptor mRNA measured in this assay are proportional to the amount of human fat cell extract added (36 Collagenase and the ingredients in the incubation buffers were from the same batches throughout the study.
Determination of hormones and metabolites. Plasma insulin and catecholamine levels were determined as described (36) . Blood glucose and lipid levels were analyzed at the hospitals routine chemistry laboratory.
Results
The mean lipolysis dose-response curves for noradrenaline and isoprenaline are depicted in Fig. 1 . Both agents caused a dose-dependent increase in lipolysis above the basal rate in both groups but the response was clearly reduced in the subjects with the metabolic syndrome. The two upper curves show results per cell number. Due to the almost twofold difference in cell size between groups, the difference in responsiveness was even more marked when lipolysis was expressed per gram lipid, as in the two lower curves in Fig. 1 . When lipolysis was stimulated at a postreceptor level with forskolin or dcAMP there was also a dose-dependent stimulation of lipolysis above the basal rate as shown in Fig. 2 . A reduction in responsiveness was found in the metabolic syndrome, irrespective of the use of denominator for lipolysis. Again the difference was more marked when lipolysis was expressed per lipid weight.
The maximum lipolytic effects of noradrenaline, isoprenaline, forskolin and dcAMP (obtained from data in Figs. 1 and 2) are evaluated in Table II . The difference between the groups was highly statistically significant for all agents irrespective of denominator (per cell or per gram of lipid) when the increase above the basal rate was calculated. The difference was even more marked when lipolysis was expressed per gram of lipid. In the subjects with the metabolic syndrome, responsiveness to isoprenaline, the most effective lipolytic agent, was reduced by 44% per cell and by as much as 75% per gram of lipid. Basal lipolysis (no agent added) was significantly increased in the subjects with the metabolic syndrome when expressed per cell but there was no statistical difference between groups when expressed per g of lipid. Table II also shows data of maximum lipolytic rates with the basal values included. Still, all significant differences between the two groups persisted except that for noradrenaline stimulated lipolysis when expressed per cell. Noradrenaline was, however, only a partial agonist in both groups causing 30-50% of the isoprenaline action (Table II) .
Adrenoceptor sensitivity was determined with the receptorselective agents terbutaline, dobutamine and clonidine. The mean dose-response curves are shown in Fig. 3 . They are depicted as percent of the maximum lipolytic effect, which is preferable when half-maximum effects (i.e., sensitivity) are evaluated, and as absolute rates per cell as well. The mean percent dose response curve for the p2-agonist terbutaline was shifted markedly to the right in the subjects with the metabolic syndrome while the curves for dobutamine and clonidine were practically superimposed in the two groups. It is also shown in Fig. 3 that the maximum lipolysis rates were reduced with both agents in the metabolic syndrome group although sensitivity (ED50) only differed between groups as regards terbutaline. When calculated on individual data, the maximum increase in lipolysis rate over basal ( gmol glycerol/ I0 7 cells) with terbuta- Isoprenaline log mol/I -11 -10
Noradrenaline log mol/l Figure 1 strongly suggests that there were no differences between the groups in the extraction of mRNA subtypes from the fat cells. Clinical data are given in Table I . As expected, the obese subjects had higher fasting blood glucose levels and insulin levels and a greater increment of plasma insulin after an oral glucose load than the control group. In addition to the three subjects who were on treatment for hypertension, five subjects had blood pressure above the WHO criteria for diagnosis of hyper- The relationship between clinical signs and the findings with fat cells were investigated using factor analysis. The corre- lation matrix is given in Table V . There was a strong correlation (-0.6 > ra> 0.6) between the degree ofglucose intolerance and the basal and maximum stimulated lipolysis rates, ,32-receptor number, and insulin sensitivity. The insulin sensitivity index correlated strongly (-0.6 > r > 0.6) with P2-receptor number, BMI, cell volume, waist/hip-ratio, fasting plasma insulin levels, and glucose tolerance.
The relationship between glucose intolerance and insulin sensitivity as dependent variables on one hand and the most important clinical and adipocyte data from the factor analysis on the other was further examined with a stepwise regression analysis. The results are summarized in Table VI. In the equation with glucose intolerance as the dependent variable, basal and maximum stimulated lipolysis were the only significant regressors. Adjusted r2 was 0.77 for these two variables. In the stepwise regression analysis with insulin sensitivity as the dependent variable, BMI, 132-receptor number and fasting plasma insulin contributed significantly to the relationship. The adjusted r2 for these regressors taken together was 0.80.
The linear relationships between glucose tolerance and isoprenaline responsiveness ( r = -0.67 ) and between insulin sensitivity and 12-receptor number (r = 0.67) are shown in Fig. 6 .
The relationship between the agonist pD2 and receptor number versus fat cell volume and basal lipolysis rate was in- 10 subjects. When data from the latter subjects were compared with the control group, the difference between groups was essentially the same as when the whole material was used.
Discussion
In this study we have for the first time examined the lipolytic function of adipocytes in the metabolic syndrome. The study was performed on elderly men with upper body obesity, reduced glucose tolerance, or NIDDM insulin resistance, and in some cases hypertension. We found a marked decrease of the catecholamine induced rate of lipolysis in fat cells from these subjects as compared to the adipocytes from healthy non-obese controls. These differences seem to be determined at different levels in the lipolytic cascade: from the binding ofthe hormone to cell surface adrenoceptors to the hydrolysis of triglycerides by the hormone sensitive lipase producing glycerol and free fatty acids.
As regards adrenoceptor function, the observed catecholamine resistance was entirely due to a ,82-receptor defect, since sensitivity to the p32-selective agonist terbutaline was markedly reduced in the obese while there was no significant difference in the sensitivity to either the ,13-selective agonist dobutamine or the a2-receptor agonist clonidine between the groups. A corresponding selective reduction by as much as 50% in the number of,32-receptor binding sites was observed in the metabolic syndrome, as evidenced from the findings with radioligand binding. This indicates that low ,B2-receptor density is one major factor for the observed hormone resistance. However, additional defects in (32-receptor coupling to Gs protein may contribute as well. Indirect evidence of this is the present observation of a negative correlation between (32-receptor sensitivity (but not 132-receptor number) and fat cell volume which was increased in the patients with the metabolic syndrome. Unfortunately, it is not possible to study coupling in small amounts ofhuman fat cells with current techniques. The steady state 131-and ,B2-mRNA levels and their ratios did not differ between the groups which indicates that the differences in 132-receptor number are determined at a posttranscriptional level. To examine these events also requires too large amounts of tissue to be included in a clinical investigation.
Recently, a third 13-adrenoreceptor (133) has been cloned. It is of major importance for lipolysis in brown fat cells in laboratory animals as discussed (37), but appears to be ofless importance for lipolysis regulation in human subcutaneous fat cells (38, 39) . The effects of the non-selective 13-agonistic agents (noradrenaline, isoprenaline) might possibly be influenced to a minor degree by the presence of 133-receptors, but not the action of the ,13-and 132-selective agents. Radioligand studies on transfected cells expressing human 133-receptors have indicated that 125-ICYP has 0-l1,000 times lower affinity for the 13-receptor than for #13-or 132-receptors (31, 32), therefore we assume that 133-receptors can not be detected with the concentrations of the radioligand used in this study as previously shown in human fat cells (38) . The unity ofthe Hill coefficient for the radioligand binding also excludes an important contribution of 133-receptors to the binding results.
The second defect in catecholamine effect was the marked suppression of the maximum lipolytic response found in the subjects with the metabolic syndrome (44-75% reduction, dependent upon the use of denominator. for the lipolysis rate). The defect was of similar magnitude when lipolysis was nonselectively stimulated through 13-receptors with isoprenaline, selectively with dobutamine or terbutaline or at different postreceptor levels with forskolin or dcAMP. These data strongly indicate alterations in the most distal steps ofthe lipolytic pathway, i.e., a decreased ability of cyclic AMP to activate the pro- (42) .
The relationsi resistance might may be a primar creased sympathy subjects (36 ry to further elucidate the relevance of these elderly male subjects. We do not know how it relates to lipolyvever, ofinterest to note that a blunted in vivo sis in other adipose regions or to catecholamine action in other to catecholamines has been found in subjects target tissues. However, the 132-receptor defect may be present obesity but not in subjects with lower-body in other fat depots of metabolic syndrome patients since there is a strong correlation between 132-receptor activity in subcutahip between the 132-receptor defect and insulin neous and visceral fat cells of healthy subjects (36) . Furtherbe causal. A decreased 132-receptor sensitivity more, it remains to be elucidated if women or younger men y cellular defect which is compensated by inwith the metabolic syndrome also are resistant to catecholetic activity as described recently in healthy amines in vitro.
ie increased catecholamine levels can in turn istance as reviewed by Smith and Lager (9) In conclusion, the present study demonstrates decreased ability of catecholamines to stimulate lipolysis in fat cells due to multiple defects in lipolysis regulation in obese elderly men suffering from the metabolic syndrome. The catecholamine resistance is secondary to a reduced expression of f32-adrenoceptors in combination with a decreased ability of cyclic AMP to activate the hormone sensitive lipase. These defects may contribute to the development of severe manifestations of the syndrome such as glucose intolerance and insulin resistance.
